Is Your Patient Eligible?

It’s estimated that about 50,000 metastatic castration-resistant prostate cancer (mCRPC) patients each year could benefit from knowing their AR-V7 status prior to selecting treatment. Patients who are resistant to androgen receptor (AR)-targeted therapies, such as abiraterone or enzalutamide, often respond to taxane chemotherapy.^1,2,3 The Oncotype DX AR-V7 Nucleus Detect test can help you confidently choose the therapy that will help offer your patients the opportunity for longer overall survival.

Eligibility criteria

The AR-V7 Nucleus Detect assay is ideal for patients who:

• Have confirmed mCRPC
• Have received and failed AR-targeted therapy
• Are considering additional AR-targeted therapies

When to order the AR-V7 Nucleus Detect test

Ordering the AR-V7 Nucleus Detect test is appropriate for patients with mCRPC whenever you’re considering AR-targeted therapy for a patient.

Why order the test before ordering AR-targeted therapies

Although AR-targeted therapies are a breakthrough in mCRPC treatment, it’s important to remember that some patients never respond to AR-targeted therapies and many patients who initially respond to AR-targeted therapies develop acquired resistance to them over time.⁴

The percentage of patients who are nuclear AR-V7+ (an absolute indicator that a patient will not respond to AR-targeted therapies) increases with each exposure to AR-targeted therapies⁵:

• Roughly 1 in 5 patients (18%) are nuclear AR-V7+ after receiving abiraterone or enzalutamide.
• Roughly 1 in 3 patients (31%) are nuclear AR-V7+ after receiving two rounds of AR-targeted therapy.

The percentage of mCRPC patients with the AR splice variant (AR-V7+) increased with continued exposure to AR-targeted therapies⁵

Cross-sectional cohort study. Blood samples were collected from 161 patients with mCRPC and tested for the presence of AR-V7.